At the COVID-19 Clinical Research Center on the Fred Hutch campus, people who recently received a positive test for SARS-CoV-2 are enrolled in trials of injectable antibodies and experimental antiviral drugs to see if these interventions may reduce the severity of symptoms and keep at risk patients out of the hospital.
New study highlights lack of diversity and inclusion in vaccine clinical trials
Analysis shows certain racial/ethnic groups and older people aren’t being adequately represented and trial reporting guidelines aren’t being followed Anthony Jackson, security coordinator for Fred Hutchinson Cancer Research Center, receives a dose of the new Pfizer-BioNTech COVID-19 vaccine on Jan. 19, 2021, at a new vaccine clinic set up on the Fred Hutch campus. Robert Hood
SEATTLE February 19, 2021 A team of scientific experts from across the U.S. and Puerto Rico are advocating for increased diversity in vaccine trials after publishing a new report that highlights a decade’s worth of disparities. The new study, published in JAMA Network Open, found that among U.S.-based vaccine clinical trials, people who are Black/African American, American Indian/Alaska Native, Hispanic/Latino and age 65 and older were the most underrepresented groups. Conversely, adult women